Life Extension Final Clerance Sale

Life Extension Magazine

Life Extension Magazine May 2014
As We See It  

CDC Says: 200,000 Americans Die Needlessly Every Year

By William Faloon

References

  1. Available at: http://www.cdc.gov/mmwr/pdf/wk/mm5021.pdf. Accessed February 13, 2014.
  2. Available at: http://www.poz.com/articles/263_16238.shtml. Accessed February 13, 2014.
  3. Available at: http://www.lef.org/offshoredrugs.htm. Accessed February 13, 2014.
  4. Pedersen C, Sandström E, Petersen CS, et al. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group. N Engl J Med. 1990 Jun 21;322(25):1757-63.
  5. Available at: http://www.cryonet.org/cgi-bin/dsp.cgi?msg=446. Accessed February 13, 2014.
  6. Available at: http://thechart.blogs.cnn.com/2013/09/03/cdc-200000-people-die-needlessly-every-year/. Accessed January 29, 2014.
  7. Available at: http://www.cdc.gov/dhdsp/vital_signs.htm. Accessed January 29, 2014.
  8. Available at: https://www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis/. Accessed February 13, 2014.
  9. Thompson RC, Allam AH, Lombardi GP, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet . 2013 Apr 6;381(9873):1211-22.
  10. Available at: http://vitals.nbcnews.com/_news/2013/03/10/17260261-mummy-study-shows-clogged-arteries-are-nothing-new?lite. Accessed February 14, 2014.
  11. Tanasescu C, Jurcut C, Jurcut R, Ginghina C. Vascular disease in rheumatoid arthritis: from subclinical lesions to cardiovascular risk. Eur J Intern Med. 2009 Jul;20(4):348-54.
  12. Szekanecz Z, Kerekes G, Dér H, et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad. Sci. 2007 Jun;1108:349-58.
  13. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 Dec 18;349(25):2399-406.
  14. Marnane M, Merwick A, Sheehan OC, et al. Carotid plaque inflammation on 18F-fluorodeoxyglucose positron emission tomography predicts early stroke recurrence. Ann Neurol. 2012 May;71(5):709-18.
  15. Corrado E, Rizzo M, Tantillo R, et al. Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: a 5-year follow-up study. Stroke. 2006 Feb;37(2):482-6.
  16. Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the cirt and cantos trials? Trans Am Clin Climatol Assoc. 2013;124:174-90.
  17. Hussein AA, Gottdiener JS, Bartz TM, et al. Inflammation and sudden cardiac death in a community-based population of older adults: The Cardiovascular Health Study. Heart Rhythm. 2013 Oct;10(10):1425-32.
  18. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997 Feb 1;79(3):350-4.
  19. Gerber RT, Holemans K, O’Brien-Coker I, et al. Cholesterol-independent endothelial dysfunction in virgin and pregnant rats fed a diet high in saturated fat. J Physiol. 1999 Jun 1;517 ( Pt 2):607-16.
  20. Wascher TC, Schmoelzer I, Wiegratz A, et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest. 2005 Sep;35(9):551-7.
  21. Piconi L, Quagliaro L, Assaloni R, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006 May-Jun;22(3):198-203.
  22. Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001 Apr 17;103(15):1936-41.
  23. Zhang S, Day I, Ye S. Nicotine induced changes in gene expression by human coronary artery endothelial cells. Atherosclerosis. 2001 Feb 1;154(2):277-83.
  24. Available at: http://www.strokeassociation.org/STROKEORG/LifeAfterStroke/HealthyLivingAfterStroke/ UnderstandingRiskyConditions/Atherosclerosis-and-Stroke_UCM_310426_Article.jsp. Accessed January 13, 2014.
  25. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013 Dec;1832(12):2216-31.
  26. Grassi D, Desideri G, Ferri C. Protective effects of dark chocolate on endothelial function and diabetes. Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):662-8.
  27. Hoffmann J, Haendeler J, Aicher A, et al. Aging enhances the sensitivity of endothelial cells toward apoptotic stimuli: important role of nitric oxide. Circ Res. 2001 Oct 12;89(8):709-15.
  28. Goettsch W, Lattmann T, Amann K, et al. Increased expression of endothelin-1 and inducible nitric oxide synthase isoform II in aging arteries in vivo: implications for atherosclerosis. Biochem Biophys Res Commun. 2001 Jan 26;280(3):908-13.
  29. de Nigris F, Williams-Ignarro S, Botti C, Sica V, Ignarro LJ, Napoli C. Pomegranate juice reduces oxidized low-density lipoprotein downregulation of endothelial nitric oxide synthase in human coronary endothelial cells. Nitric Oxide. 2006 Nov;15(3):259-63.
  30. Ignarro LJ, Byrns RE, Sumi D, de Nigris F, Napoli C. Pomegranate juice protects nitric oxide against oxidative destruction and enhances the biological actions of nitric oxide. Nitric Oxide. 2006 Sep;15(2):93-102.
  31. Kelishadi R, Gidding SS, Hashemi M, Hashemipour M, Zakerameli A, Poursafa P. Acute and long term effects of grape and pomegranate juice consumption on endothelial dysfunction in pediatric metabolic syndrome. J Res Med Sci. 2011 Mar;16(3):245-53.
  32. Potenza MA, Marasciulo FL, Tarquinio M, et al. EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab. 2007 May;292(5):E1378-87.
  33. Kim JA, Formoso G, Li Y, et al. Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent vasodilation using signaling pathways in vascular endothelium requiring reactive oxygen species and Fyn. J Biol Chem. 2007 May 4;282(18):13736-45.
  34. Lorenz M, Wessler S, Follmann E, et al. A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. J Biol Chem. 2004 Feb 13;279(7):6190-5.
  35. Takizawa Y, Kosuge Y, Awaji H, et al. Up-regulation of endothelial nitric oxide synthase (eNOS), silent mating type information regulation 2 homologue 1 (SIRT1) and autophagy-related genes by repeated treatments with resveratrol in human umbilical vein endothelial cells. Br J Nutr. 2013 Dec;110(12):2150-5.
  36. Caimi G, Carollo C, Lo PR. Wine and endothelial function. Drugs Exp Clin Res. 2003 29(5-6):235-42.
  37. van de Wiel A. Nutrition and health—favorable effect of wine and wine flavonoids on cardiovascular diseases. Ned Tijdschr Geneeskd. 2002 Dec 21;146(51):2466-9.
  38. Gresele P, Pignatelli P, Guglielmini G, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr. 2008 Sep;138(9):1602-8.
  39. Freedman JE, Parker C 3rd, Li L, et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation. 2001 Jun 12;103(23):2792-8.
  40. Esper RJ, Vilariño JO, Machado RA, Paragano A. Endothelial dysfunction in normal and abnormal glucose metabolism. Adv Cardiol. 2008 45:17-43.
  41. Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol. 2005 Nov 1;96(9):1273-7.
  42. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation. 1998 May 5;97(17):1695-701.
  43. Stochmal E, Szurkowska M, Czarnecka D, et al. Association of coronary atherosclerosis with insulin resistance in patients with impaired glucose tolerance. Acta Cardiol. 2005 Jun;60(3):325-31.
  44. Karrowni W, Li Y, Jones PG, et al. Insulin resistance is associated with significant clinical atherosclerosis in nondiabetic patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2245-51.
  45. Gage MC, Yuldasheva NY, Viswambharan H, et al. Endothelium-specific insulin resistance leads to accelerated atherosclerosis in areas with disturbed flow patterns: a role for reactive oxygen species. Atherosclerosis. 2013 Sep;230(1):131-9.
  46. Jagla A, Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes. 2001 109(4):S533-47.
  47. Sokup A, Góralczyk B, Góralczyk K, Rość D. Triglycerides as an early pathophysiological marker of endothelial dysfunction in nondiabetic women with a previous history of gestational diabetes. Acta Obstet Gynecol Scand. 2012 Feb;91(2):182-8.
  48. Toma L, Stancu CS, Botez GM, Sima AV, Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun. 2009 Dec 18;390(3):877-82.
  49. De CR, Lenzi S. The role of LDL in the origin and progression of atherosclerosis: pathobiological concepts on the origin and development of atherosclerotic lesions and the role of the endothelium. G Ital Cardiol. 1998 Feb;28(2):158-67.
  50. Chen G, Qin XP, Lin J, Wang JJ, Zhou N, Li J. Minimally modified LDL induced impairment of endothelium-dependent relaxation in mesenteric arteries of mice. Yao Xue Xue Bao. 2013 Nov;48(11):1657-64.
  51. Dardik R, Varon D, Tamarin I, et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost. 2000 Feb;83(2):338-44.
  52. Hassan A, Hunt BJ, O’Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain . 2004 Jan;127(Pt 1):212-9.
  53. Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation. 1997 Oct 21;96(8):2542-4.
  54. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000 Oct 31;102(18):2165-8.
  55. Available at: http://dvr.sagepub.com/content/10/6/550.abstract. Accessed February 20, 2014.
  56. Schalkwijk CG1, Poland DC, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999 Mar;42(3):351-7.
  57. Silva BR, Pernomian L, Bendhack LM. Contribution of oxidative stress to endothelial dysfunction in hypertension. Front Physiol. 2012 Dec 5;3:441.
  58. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag. 2005;1(3):183-98.
  59. Chrissobolis S, Miller AA, Drummond GR, Kemp-Harper BK, Sobey CG. Oxidative stress and endothelial dysfunction in cerebrovascular disease. Front Biosci (Landmark Ed). 2011 Jan 1;16:1733-45.
  60. Toikka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999 Nov 1;147(1):133-8.
  61. Campbell S, Genest J. HDL-C: clinical equipoise and vascular endothelial function. Expert Rev Cardiovasc Ther. 2013 Mar;11(3):343-53.
  62. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-densitylipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol. 2003 Oct 1;23(10):1724-31.
  63. Ong PJ, Patrizi G, Chong WC, Webb CM, Hayward CS, Collins P. Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. J Cardiol. 2000 Jan 15;85(2):269-72.
  64. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005 5(3):141-54.
  65. Bełtowski J. Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw (Online). 2005 59:392-404.
  66. Liao D, Tan H, Hui R, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res. 2006 Sep 15;99(6):598-606.
  67. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. J Nutr. 2000 Feb;130(2S Suppl):369S-372S.
  68. Jacobsen DW, Catanescu O, Dibello PM, Barbato JC. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med. 2005 43(10):1076-83.
  69. Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost. 2003 Feb;1(2):300-6.
  70. Available at: http://www.lef.org/magazine/mag2003/nov2003_awsi_01.htm?source=search&key=homocysteine. Accessed January 13, 2014.
  71. Available at: http://www.lef.org/magazine/mag99/mar99-report2.html?source=search&key=homocysteine. Accessed January 13, 2014.
  72. Available at: http://www.lef.org/magazine/mag2006/jun2006_report_doctors_01.htm?source=search&key=homocysteine. Accessed January 13, 2014.
  73. Available at: http://www.lef.org/magazine/mag2010/dec2010_Why-Reading-Mainstream-Magazines-Can-be-Detrimental-to-Your-Health_02.htm?source=search&key=homocysteine. Accessed January 13, 2014.
  74. Available at: http://www.lef.org/magazine/mag2005/apr2005_awsi_01.htm?source=search&key=homocysteine. Accessed January 13, 2014.
  75. Celermajer DS, Sorensen K, Ryalls M, et al. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 1993 Sep;22(3):854-8.
  76. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med. 2009;60:39-54.
  77. Moustapha A, Robinson K. Homocysteine: an emerging age-related cardiovascular risk factor. Geriatrics. 1999 Apr;54(4):41,44-6,49-51.
  78. Xiao Y, Zhang Y, Wang M, Li X, Xia M, Ling W. Dietary protein and plasma total homocysteine, cysteine concentrations in coronary angiographic subjects. Nutr J. 2013 Nov 7;12(1):144.
  79. O’Callaghan P, Meleady R, Fitzgerald T, Graham I. Smoking and plasma homocysteine. Eur Heart J. 2002 Oct;23(20):1580-6.
  80. Hak AE, Polderman KH, Westendorp IC, et al. Increased plasma homocysteine after menopause. Atherosclerosis. 2000 Mar;149(1):163-8.
  81. Dankner R, Chetrit A, Lubin F, Sela BA. Life-style habits and homocysteine levels in an elderly population. Aging Clin Exp Res. 2004 Dec;16(6):437-42.
  82. Refsum H1, Nurk E, Smith AD, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006 Jun;136(6 Suppl):1731S-1740S.
  83. Saw SM, Yuan JM, Ong CN, et al. Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am J Clin Nutr. 2001 Feb;73(2):232-9.
  84. de la Torre JC. Critical threshold cerebral hypoperfusion causes Alzheimer’s disease? Acta Neuropathol. 1999 Jul;98(1):1-8.
  85. Kim HA, Miller AA, Drummond GR, et al. Vascular cognitive impairment and Alzheimer’s disease: role of cerebral hypoperfusion and oxidative stress. Naunyn Schmiedebergs Arch Pharmacol. 2012 Oct;385(10):953-9.
  86. Nishimura T, Hashikawa K, Fukuyama H, et al. Decreased cerebral blood flow and prognosis of Alzheimer’s disease. Ann Nucl Med. 2007 Jan;21(1):15-23.
  87. Hooshmand B, Polvikoski T, Kivipelto M, et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain. 2013 Sep;136(Pt 9):2707-16.
  88. Grueter BE, Schulz UG. Age-related cerebral white matter disease (leukoaraiosis): a review. Postgrad Med J. 2012 Feb;88(1036):79-87.
  89. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010 Sep 8;5(9):e12244.
  90. Waśkiewicz A, Sygnowska E, Broda G. Dietary intake of vitamins B6, B12 and folate in relation to homocysteine serum concentration in the adult Polish population - WOBASZ Project. Kardiol Pol. 2010 Mar;68(3):275-82.
  91. Lewerin C, Nilsson-Ehle H, Matousek M, Lindstedt G, Steen B. Reduction of plasma homocysteine and serum methylmalonate concentrations in apparently healthy elderly subjects after treatment with folic acid, vitamin B12 and vitamin B6: a randomised trial. Eur J Clin Nutr. 2003 Nov;57(11):1426-36.
  92. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA. 2002 Aug 28;288(8):973-9.
  93. Chen RY, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab. 2006 Jul;8(4):429-35.
  94. Abate N, Haffner SM, Garg A, Peshock RM, Grundy SM. Sex steroid hormones, upper body obesity, and insulin resistance. J Clin Endocrinol Metab. 2002 Oct;87(10):4522-7.
  95. Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008 May;93(5):1834-40.
  96. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl. 2009 Jan-Feb;30(1):23-32.
  97. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9.
  98. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005 5(3):141-54.
  99. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. J Am Coll Cardiol. 2011 Oct 11;58(16):1674-81.
  100. Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013 Nov;98(11):4300-10.
  101. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2013 Oct 15.
  102. Available at: http://www.medicinenet.com/metabolic_syndrome/article.htm. Accessed January 13, 2014.
  103. Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf. 2004 Nov;3(6):599-606.
  104. Available at: http://www.cdc.gov/media/dpk/2013/dpk-vs-heart-disease.html. Accessed January 13, 2014.
  105. Available at: http://www.cbsnews.com/8301-250_162-57597162/george-w-bush-undergoes-heart-procedure/. Accessed Jan. 13, 2014.
  106. Available at: http://www.lef.org/magazine/mag2006/may2006_awsi_01.htm. Accessed January 13, 2014.
  107. Available at: http://www.lef.org/protocols/heart_circulatory/stroke_cerebrovascular_disease_04.htm#risk. Accessed January 13, 2014.
  108. Available at: http://www.lef.org/magazine/mag2007/may2007_awsi_01.htm?source=search&key=daggers. Accessed January 13, 2014.
  109. Available at: http://web2.airmail.net/uthman/pres_longev.html. Accessed February 21, 2014.
  110. Available at: >http://starship.python.net/crew/manus/Presidents/faq/causes.html. Accessed February 21, 2014.
  111. Available at: http://usatoday30.usatoday.com/news/nation/2004-09-05-clinton-bypass_x.htm. Accessed January 13, 2014.
  112. Available at: http://www.nytimes.com/2005/03/09/national/09surgery.html?_r=0. Accessed January 13, 2014.
  113. Available at: http://www.buffalohearthealth.com/?p=4219. Accessed January 13, 2014.
  114. Available at: http://online.wsj.com/news/articles/SB10001424052702304066404579125204086074282. Accessed January 13, 2014.
  115. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/index2.html. Accessed January 13, 2014.
  116. Cheney D and Reiner J. Heart: An American Medical Odyssey. Scribner; 2013.
  117. Chang J, Zhang G, Zhang L, Hou YP, Liu XL, Zhang L. High admission glucose levels increase Fas apoptosis and mortality in patients with acute ST-elevation myocardial infarction: a prospective cohort study. Cardiovasc Diabetol. 2013 Nov 15;12(1):171.
  118. Squire IB, Nelson CP, Ng LL, Jones DR, Woods KL, Lambert PC. Prognostic value of admission blood glucose concentration and diabetes diagnosis on survival after acute myocardial infarction: results from 4702 index cases in routine practice. Clin Sci (Lond). 2010 Apr;118(8):527-35.
  119. Vujosevic S, Radojevic N, Belada N. Influence of admission glucose profile and hemoglobin A1c on complications of acute myocardial infarction in diabetic patients. Eur Rev Med Pharmacol Sci. 2013 May;17(9):1252-7.
  120. Pai JK, Cahill LE, Hu FB, Rexrode KM, Manson JE, Rimm EB. Hemoglobin a1c is associated with increased risk of incident coronary heart disease among apparently healthy, nondiabetic men and women. J Am Heart Assoc. 2013 Mar 22;2(2):e000077.
  121. Naito R, Miyauchi K, Ogita M, et al. Impact of admission glycemia and glycosylated hemoglobin A1c on long-term clinical outcomes of non-diabetic patients with acute coronary syndrome. J Cardiol. 2013 Sep 4.
  122. Available at: http://www.lef.org/magazine/mag2011/jan2011_Glucose-The-Silent-Killer_01.htm. Accessed January 13, 2014.
  123. Available at: http://www.lef.org/magazine/mag2013/jul2013_Blood-Levels-of-Insulin-and-Hemoglobin-A1c-in-Foundation-Members_01.htm?source=search&key=hemoglobin%20a1c%205.6. Accessed February 21, 2014.
  124. Available at: http://www.lef.org/magazine/mag2009/may2009_Heart-Attack-Risk-Factors_01.htm. Accessed January 13, 2014.
  125. Tomas M, Latorre G, Senti M, Marrugat J. The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis. Rev Esp Cardiol. 2004 Jun;57(6):557-69.
  126. Navab M, Anantharamaiah GM, Fogelman AM. The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med. 2005 May;15(4):158-61.
  127. Spieker LE, Ruschitzka F, Lüscher TF, Noll G. HDL and inflammation in atherosclerosis. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Mar;4(1):51-7.
  128. Ashby DT, Rye KA, Clay MA, Vadas MA, Gamble JR, Barter PJ. Factors influencing the ability of HDL to inhibit expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1450-5.
  129. Nofer JR, Brodde MF, Kehrel BE. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol. 2010 Jul;37(7):726-35.
  130. Mackness MI, Durrington PN, Mackness B. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004 4(4):211-7.
  131. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation. 2003 Jun 10;107(22):2775-9.
  132. Mackness M, Boullier A, Hennuyer N, et al. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000 Mar 5;269(1):232-6.
  133. Cakatay U, Kayali R, Uzun H. Relation of plasma protein oxidation parameters and paraoxonase activity in the ageing population. Clin Exp Med. 2008 Mar;8(1):51-7.
  134. Marchegiani F, Marra M, Spazzafumo L, et al. Paraoxonase activity and genotype predispose to successful aging. J Gerontol A Biol Sci Med Sci. 2006 Jun;61(6):541-6.
  135. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun. 2004 Jun 4;318(3):680-3.
  136. Graner M, James RW, Kahri J, et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol. 2006 Jun 20;47(12):2429-35.
  137. Soran H, Younis NN, Charlton-Menys V, Durrington P. Variation in paraoxonase-1 activity and atherosclerosis. Curr Opin Lipidol. 2009 Aug;20(4):265-74.
  138. Aviram M, Rosenblat M. Pomegranate for your cardiovascular health. Rambam Maimonides Med J. 2013 Apr 30;4(2):e0013.
  139. Rosenblat M, Aviram M. Paraoxonases role in the prevention of cardiovascular diseases. Biofactors. 2009 Jan-Feb;35(1):98-104.
  140. Gouedard C, Barouki R, Morel Y. Induction of the paraoxonase-1 gene expression by resveratrol. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2378-83.
  141. Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun. 2008 Sep 12;374(1):55-9.
  142. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol. 2011 Feb 1;81(3):337-44.
  143. Aviram M, Rosenblat M, Gaitini D, et al. Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr. 2004 Jun;23(3):423-33.